|
| Author (origin) | Study design | Two-Step group | One-Step group | GDM rate | Primary outcome |
|
| Duran et al., 2014 (Spain) [22] | Retroprospective cohort | ACOG: 50 g 1 h GCT; if >140 mg/dL followed by 100 g 3 h GTT (C&C) | IADPSG: 75 g 2 h GTT | 10.6% versus 35.5% | Pregnancy outcomes |
| Fuller and Borgida, 2014 (USA) [23] | Retroprospective cohort | ACOG: 50 g 1 h GCT; if >135 mg/dL followed by 100 g 3 h GTT (C&C) | IADPSG: 75 g 2 h GTT | 7.0% versus 11.7% | Maternal and delivery outcomes |
| Liu et al., 2014 (China) [24] | Retrospective cohort | ACOG: 50 g 1 h GCT; if >140 mg/dL followed by 100 g 3 h GTT (C&C) | IADPSG: 75 g 2 h GTT | 7.0% versus 20.4% | Maternal and perinatal outcomes |
| Oriot et al., 2014 (Belgium) [25] | Retrospective cohort | ACOG: 50 g 1 h GCT; if >140 mg/dL followed by 100 g 3 h GTT (C&C) | IADPSG: 75 g 2 h GTT | 8.0% versus 23.0% | CS, macrosomia |
| Wei et al., 2014 (China) [26] | Retrospective cohort | ACOG: 50 g 1 h GCT; if >135 mg/dL followed by 75 g 3 h GTT (NDDG) | IADPSG: 75 g 2 h GTT | 18.3% versus 21.0% | CS, macrosomia |
| Hung and Hsieh, 2015 (Taiwan) [27] | Retrospective cohort | ACOG: 50 g 1 h GCT; if >140 mg/dL followed by 100 g 3 h GTT (C&C) | IADPSG: 75 g 2 h GTT | 4.6% versus 12.4% | Macrosomia, LGA |
| Kong et al., 2015 (Canada) [28] | Retrospective cohort | ACOG: 50 g 1 h GCT; if >140 mg/dL followed by 100 g 3 h GTT (C&C) | IADPSG: 75 g 2 h GTT | 7.9% versus 9.4% | Maternal and fetal outcomes |
| Assaf-Balut et al., 2016 (Spain) [29] | Retrospective cohort | ADA: 50 g 1 h GCT; if >140 mg/dL followed by 100 g 3 h GTT (C&C) | IADPSG: 75 g 2 h GTT | Not stated | Postpartum disorders |
| Klara Feldman et al., 2016 (USA) [30] | Retroprospective cohort | ACOG: 50 g 1 h GCT; if >130 mg/dL followed by 100 g 3 h GTT (C&C) | IADPSG: 75 g 2 h GTT if HbA1c < 5.7% | 17.0% versus 27.0% | Pregnancy outcomes |
|
